By Billy Candra 
Mammograms, traditionally recognized as a cornerstone in the early detection of breast cancer, are poised to transcend their primary diagnostic role, potentially offering crucial insights into women’s cardiovascular health with the integration of advanced artificial intelligence (AI) models. A groundbreaking study, slated for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.25), unveils how these routine cancer screening tools can be leveraged to quantify calcium buildup in the arteries within breast tissue – a potent and often overlooked indicator of cardiovascular disease risk. This revelation promises to transform mammography into an opportunistic screening platform, addressing the critical challenge of underdiagnosed heart disease in women.
The Untapped Potential of Routine Mammograms
The U.S. Centers for Disease Control and Prevention (CDC) advocates for regular mammographic screening for middle-aged and older women, typically every one or two years, resulting in approximately 40 million mammograms performed annually across the United States. While breast artery calcifications (BAC) are frequently visible on these X-ray images, their significance as a cardiovascular biomarker has historically been underappreciated and, critically, largely unreported by radiologists to patients or their referring clinicians. This new research introduces an innovative AI-driven image analysis technique, previously unexplored in mammography, designed to automatically detect, quantify, and translate breast arterial calcification into a comprehensive cardiovascular risk score. The study, a collaborative effort between Emory Healthcare and Mayo Clinic, highlights a significant opportunity to bridge an existing gap in proactive cardiovascular risk assessment.
Dr. Theo Dapamede, a postdoctoral fellow at Emory University in Atlanta and the study’s lead author, underscored the dual benefit of this approach: "We see an opportunity for women to get screened for cancer and also additionally get a cardiovascular screen from their mammograms. Our study showed that breast arterial calcification is a good predictor for cardiovascular disease, especially in patients younger than age 60. If we are able to screen and identify these patients early, we can refer them to a cardiologist for further risk assessment." This dual screening potential is particularly impactful given that heart disease remains the leading cause of death in the United States, yet it continues to be underdiagnosed in women, compounded by a persistent lack of awareness regarding its symptoms and risk factors among the female population.
Understanding Breast Arterial Calcification (BAC)
A buildup of calcium in the walls of blood vessels, known as calcification, is a recognized marker of vascular damage associated with the early stages of atherosclerotic heart disease or the natural aging process. While arterial calcification can occur in various parts of the body, its presence in the breast arteries, or breast arterial calcification (BAC), has been a subject of increasing scientific interest over the past few decades. Unlike breast parenchymal calcifications, which are often associated with benign or malignant breast lesions, BAC is a distinct entity occurring within the arterial walls. Previous research, including a meta-analysis published in the journal Circulation, has consistently demonstrated a strong correlation between BAC and an elevated risk of cardiovascular events. Specifically, women identified with calcium buildup in their breast arteries have been shown to face a 51% higher risk of experiencing heart disease and stroke compared to those without.
Despite this known association, the routine quantification and reporting of BAC on mammograms have not been standard clinical practice. This oversight stems from several factors, including the time-consuming nature of manual assessment, the subjective variability inherent in human interpretation, and the absence of clear guidelines or established clinical pathways for managing incidentally detected BAC. The sheer volume of mammograms performed annually further underscores the impracticality of manual assessment on a large scale.
The AI Breakthrough: Deep Learning and Segmentation
The innovation at the heart of this study lies in its sophisticated application of deep learning AI. Researchers developed and trained a deep-learning AI model to precisely identify and "segment" calcified vessels within mammogram images. On an X-ray, these calcifications manifest as bright, distinct pixels. What distinguishes this particular AI model from earlier attempts to analyze breast artery calcifications is its advanced segmentation approach. Rather than merely detecting the presence of calcification, the model accurately delineates the boundaries of these calcified structures, allowing for a more precise quantification of their extent.
This granular segmentation enables the AI to calculate the future risk of cardiovascular events with greater accuracy. The model was trained and rigorously tested using an exceptionally large and robust dataset: images and comprehensive electronic health records (EHR) from over 56,000 patients who underwent mammograms at Emory Healthcare between 2013 and 2020. Critically, each patient had at least five years of follow-up EHR data, providing a long-term perspective on their health outcomes and allowing the AI to learn from real-world progression of disease. This extensive dataset and the novel segmentation technique bolster the model’s predictive power and reliability.
Dr. Dapamede emphasized the broader implications of such technological advancements, stating, "Advances in deep learning and AI have made it much more feasible to extract and use more information from images to inform opportunistic screening." This sentiment reflects a growing trend in medical imaging, where AI is increasingly seen as a tool not just for automating tasks, but for uncovering previously hidden diagnostic information within existing medical data.
Study Findings: Early Warning for Younger Women
The overall findings of the study demonstrate the new AI model’s impressive capability in accurately characterizing patients’ cardiovascular risk as low, moderate, or severe, solely based on their mammogram images. The model was tasked with calculating the risk of death from any cause or suffering an acute heart attack, stroke, or heart failure at two and five-year intervals.
The results revealed a clear and concerning pattern: the rate of serious cardiovascular events increased proportionally with the level of breast arterial calcification in two critical age categories – women younger than 60 and those aged 60-80. Notably, this correlation was less pronounced in women over 80, suggesting that for older populations, other pre-existing comorbidities and generalized vascular aging might diminish the singular predictive power of BAC. This particular finding makes the AI-enabled tool exceptionally well-suited for providing an early warning of heart disease risk in younger women, a demographic that stands to benefit most significantly from early interventions and lifestyle modifications.
Further statistical analysis underscored the gravity of these findings. Women with the highest level of breast arterial calcification (quantified above 40 mm²) exhibited a significantly lower five-year rate of event-free survival compared to those with the lowest level (below 10 mm²). For instance, only 86.4% of women in the highest BAC category survived for five years without a major cardiovascular event, in stark contrast to 95.3% of those with the lowest level of calcification. This translates to an approximate 2.8 times higher risk of death within five years for patients with severe breast arterial calcification compared to those with little to no BAC. These are compelling statistics that highlight the clinical utility of this AI-driven assessment.
Broader Context: Women’s Cardiovascular Health Disparities
The potential of AI-enabled mammography to identify cardiovascular risk is particularly pertinent in the context of women’s cardiovascular health. Historically, heart disease has been perceived as primarily a "man’s disease," leading to significant disparities in diagnosis, treatment, and research for women. Women often present with atypical symptoms of heart attack, leading to delayed diagnosis. Furthermore, traditional cardiovascular risk assessment tools, such as the Framingham Risk Score, have sometimes underestimated risk in women, prompting a call for sex-specific risk factors and screening methods.
Conditions such as preeclampsia, gestational diabetes, and certain autoimmune diseases, unique to women, are now recognized as significant long-term risk factors for cardiovascular disease. Yet, these factors are not always systematically integrated into routine screening. The ability to leverage an existing, widely performed screening test like mammography to glean additional, critical information about heart health represents a paradigm shift. It offers an "opportunistic screening" model, catching potential issues early in a population already engaged in preventive health. This could lead to earlier referrals to cardiologists, proactive management of modifiable risk factors (e.g., hypertension, dyslipidemia, diabetes), and ultimately, improved long-term outcomes for countless women.
Implications for Clinical Practice and Public Health
The integration of this AI model into routine mammogram processing could have profound implications for clinical practice and public health. For radiologists, it could mean an automated, objective, and standardized method for assessing BAC, freeing them from manual measurement and providing a clinically actionable report. For primary care physicians and cardiologists, it offers a new, cost-effective screening tool that capitalizes on an already scheduled appointment, circumventing the need for additional, potentially costly or invasive cardiovascular imaging tests in all women.
The economic burden of cardiovascular disease in the U.S. is immense, projected to reach over $1.1 trillion by 2035, including both direct medical costs and indirect costs from lost productivity. Early detection and intervention, facilitated by tools like this AI model, have the potential to significantly reduce these costs by preventing advanced disease requiring complex and expensive treatments. From a public health standpoint, integrating this technology could significantly enhance population-level cardiovascular risk stratification, particularly in younger women who might otherwise be considered low-risk by conventional metrics until symptoms manifest.
The Path Forward: Validation, Regulation, and Integration
While the study’s results are highly promising, the AI model developed by Emory Healthcare and Mayo Clinic is not yet commercially available for clinical use. The next critical steps involve rigorous external validation to ensure its performance generalizes across diverse patient populations and different imaging systems. Following successful validation, the tool will need to navigate the stringent regulatory approval process of the U.S. Food and Drug Administration (FDA). This process typically involves demonstrating safety, effectiveness, and clinical utility.
Should it gain FDA approval, researchers anticipate that the tool could be made commercially available, allowing other healthcare systems to incorporate it into their routine mammogram processing and follow-up care pathways. This would necessitate developing clear clinical guidelines for how to manage and communicate BAC findings to patients and how to integrate these scores into existing cardiovascular risk assessment algorithms. Training for radiologists and other healthcare providers would also be essential to ensure appropriate interpretation and action.
Beyond cardiovascular health, the research team is already exploring the broader applicability of similar AI models. They plan to investigate how AI could be used to extract other valuable biomarkers from mammograms for assessing conditions such as peripheral artery disease and kidney disease. This vision positions mammography not merely as a breast cancer screening tool, but as a potential gateway to comprehensive women’s health assessment, unlocking a wealth of diagnostic information from existing imaging data.
The advent of AI-powered mammography marks a significant leap forward in personalized medicine and preventive care. By transforming a routine cancer screening into a sophisticated, dual-purpose diagnostic tool, this innovation holds the promise of dramatically improving the early detection of cardiovascular disease in women, ultimately leading to earlier interventions, better health outcomes, and a more holistic approach to women’s health.
